fingolimod hydrochloride has been researched along with Atrioventricular Block in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canpolat, M; Kum, YE; Pamukçu, Ö | 1 |
| Brown, B; Kolodny, S; Meng, X; Osborne, JA; Weiss, JL; Williams, IM | 1 |
| Feige, J; Schernthaner, C; Sellner, J; Wipfler, P | 1 |
| Filippi, M; Gelibter, S; Moiola, L; Nozzolillo, A; Orrico, M; Preziosa, P; Sangalli, F | 1 |
| Keane, D; O'Kelly, S; Saiva, L; Voon, V | 1 |
| Brogi, D; Comi, G; Guidi, L; Laroni, A; Lugaresi, A; Mancardi, GL; Morra, VB; Pozzilli, C; Raimondi, D; Turrini, R; Uccelli, A | 1 |
| Botto, G; Pentimalli, F; Vanoli, E | 1 |
| Höjer, J; Olsson, E | 1 |
| Ando, K; Cao, X; Harada, T; Izumi-Nakaseko, H; Kato, K; Kitahara, K; Nakamura, Y; Ninomiya, T; Ohara, H; Sugiyama, A; Suzuki, K; Yagi, Y | 1 |
| Fellows, SE; Nomura, JT; Rajasimhan, S; Rosini, JM | 1 |
| D'Onghia, M; Direnzo, V; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S | 1 |
| Brescia Morra, V; Cittadini, A; De Angelis, G; de Rosa, A; Lanzillo, R; Marsili, A; Pane, C; Puorro, G; Russo, CV; Saccà, F | 1 |
| Bush, J; Camm, AJ; de La Borderie, G; Harada, T; Inoue, S; Wilbraham, D | 1 |
| Albert, C; Baier-Ebert, M; Dechend, R; Gerbershagen, K; Haas, J; Haverkamp, W; Hoffmann, O; Hoyer, S; Klotz, L; Lang, M; Lassek, C; Limmroth, V; Richter, S; Schieb, H; Schmidt, S; Schuh, K; Wagner, B; Wendt, G; Ziemssen, T | 1 |
| Merkely, B; Széplaki, G | 1 |
2 review(s) available for fingolimod hydrochloride and Atrioventricular Block
| Article | Year |
|---|---|
Vagomimetic effects of fingolimod: physiology and clinical implications.
Topics: Animals; Atrioventricular Block; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2014 |
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Topics: Atrioventricular Block; Bradycardia; Cardiovascular System; Clinical Trials as Topic; Drug Administration Schedule; Fingolimod Hydrochloride; Heart Conduction System; Humans; Hypertension; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Treatment Outcome | 2012 |
2 trial(s) available for fingolimod hydrochloride and Atrioventricular Block
| Article | Year |
|---|---|
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Topics: Adolescent; Adult; Atrioventricular Block; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
Topics: Adult; Atrioventricular Block; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography, Ambulatory; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Propanolamines; Receptors, Lysosphingolipid; Single-Blind Method; Young Adult | 2017 |
11 other study(ies) available for fingolimod hydrochloride and Atrioventricular Block
| Article | Year |
|---|---|
Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Topics: Adolescent; Atrioventricular Block; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2023 |
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
Topics: Adult; Atrioventricular Block; Electroencephalography; Female; Fingolimod Hydrochloride; Heart Rate; Home Care Services, Hospital-Based; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Satisfaction; Retrospective Studies | 2019 |
Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
Topics: Atrioventricular Block; Cardiac Resynchronization Therapy Devices; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
Topics: Atrioventricular Block; COVID-19; Fingolimod Hydrochloride; Humans; Lysophospholipids; Pandemics; SARS-CoV-2; Sphingosine | 2021 |
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Topics: Administration, Oral; Atrioventricular Block; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2014 |
AV block II in a toddler after ingestion of a single tablet fingolimod.
Topics: Atrioventricular Block; Child, Preschool; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Propylene Glycols; Sphingosine | 2014 |
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Topics: Animals; Atrioventricular Block; Brugada Syndrome; Cardiac Conduction System Disease; Fingolimod Hydrochloride; Guinea Pigs; Heart Conduction System; HEK293 Cells; Humans; Immunosuppressive Agents; Long QT Syndrome; Male; Receptors, Lysosphingolipid | 2014 |
Delayed cardiac dysrhythmias after fingolimod administration.
Topics: Atrioventricular Block; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Propylene Glycols; Sphingosine; Tachycardia, Ectopic Junctional; Time Factors | 2015 |
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Topics: Adult; Atrial Fibrillation; Atrioventricular Block; Blood Pressure; Electrocardiography; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Product Surveillance, Postmarketing | 2015 |
Mobitz type I and II atrioventricular blocks during fingolimod therapy.
Topics: Adult; Atrioventricular Block; Electrocardiography; Electroencephalography; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Topics: Adult; Aged; Atrioventricular Block; Bradycardia; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2017 |